Navigation Links
Scientists Rediscover Gene Target for Cancer Therapy
Date:12/15/2009

SAN MARINO, Calif., Dec. 15 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies. Recently, scientists at the NIH National Cancer Institute investigating the role of microRNAs (miRNAs) in tumor development and their utility to serve as biomarkers for cancer diagnosis and prognosis identified one particular species of miRNA (designated miR-122) that was linked to both the development and the aggressiveness of liver cancer (Coulouran et al., Oncogene, 2009).

While microRNAs are natural negative regulators of protein coding genes, miR-122 is characteristically suppressed in hepatocelluar carcinomas, and conversely its "therapeutic" re-expression was found to reverse the tumorigenic properties of the cancer cells in terms of growth, replication potential, invasion, and tumor formation (Bai et al., J Biol Chem, 2009). Scientists working in Italy and the USA, using miRNA libraries as probes in high throughput microarray assays to screen for sequences that are dysregulated in human cancers, independently implicated miR-122 in the pathogenesis of liver cancer and further demonstrated that the tumor suppressive action of this particular mRNA is manifested through the inhibition of the Cyclin G1 gene (Gramantieri et al., Cancer Res, 2009).

The finding that the natural suppression of the Cyclin G1 gene is lost in cancer cells is not at all surprising to scientists at Epeius Biotechnologies, who first identified the human Cyclin G1 gene as a proto-oncogene in 1994, demonstrated its therapeutic potential in a comprehensive series of landmark studies (1995-2005), and designed the sophisticated dominant-negative "knockout" construct embodied in the powerful anti-cancer agent Rexin-G (see Gordon and Hall, Intl. J. Oncology, 2009).

According to Dr. Frederick L. Hall, President and CEO of Epeius Biotech, "It is gratifying to find that functional genomics and high-throughput screening have finally served to direct basic research away from simplistic antibodies and superficial blockades of receptor-mediated pathways to the crux of the matter and the final common pathways of cell cycle control. Moreover, it is always reassuring when a basic mechanistic understanding of the logic and executive enzymology of a biochemical pathway serves to trump the rolling of dice." The finding that miR-121 targets Cyclin G1 gene expression confirms that Rexin-G may indeed be restoring a natural tumor suppressor function that is lost in the development and progression of many types of cancer; while the pathotropic (or disease-seeking) properties of Rexin-G function to deliver this agreeably rational and strategic anti-cancer agent precisely where it is needed most.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted gene delivery systems. Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors by the Philippine FDA, and has recently received three Orphan Drug priorities and Fast Track designation by the U.S. FDA. Please visit us at http://www.epeiusbiotech.com .

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

*(LOGO 72dpi: Send2Press.com/mediaboom/09-1012-EpeiusBio_72dpi.jpg)

SOURCE Epeius Biotechnologies Corporation


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
2. Scientists demonstrate multibeam, multi-functional lasers
3. Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva
4. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
5. Scientists develop novel method to generate functional hepatocytes for drug testing
6. Harvard scientists bend nanowires into 2-D and 3-D structures
7. Scientists use math modeling to predict unknown biological mechanism of regulation
8. Weed Scientists Take Steps to Protect Rare Orchid
9. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
10. Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers
11. UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing ... disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):